The Chase Group is pleased to announce our recent partnership and executive search engagement with the international biopharmaceutical company, Immunovative Therapies, Ltd. (ITL), currently headquartered in Israel with locations in the United States and Bangkok, Thailand. Mirror Biologics (MBI), a wholly-owned subsidiary of ITL, will be based in the United States and will be the world headquarters for the ITL family of companies. MBI has partnered with The Chase Group to recruit an executive management team and board of directors to assist in the advancement of ITL current products to commercialization. The CEO recruited will establish the strategic direction, lead fund raising, and will direct the operations of ITL and its subsidiaries.Immunovative Therapies has developed a core immunotherapy technology platform for the development of a new type of “off-the-shelf” therapeutic cancer vaccine. The platform and the products in clinical development are protected by over 200 issued patents worldwide.When established, this new executive team will lead the multi-national, clinical Phase II immuno-oncology company to pivotal Phase III trials, IPO, and first commercial revenues. MBI will establish a corporate headquarters for their executive management team as well as create a bioengineering, bioprocessing, and prototype development operation to develop an automated, closed, sterile, scalable pilot scale production system for the commercial scale production of its living cell products, disposables, and reagents. All efforts will be coordinated with the Jerusalem, Phoenix, and Bangkok operations.Immunovative Therapies is driven to develop innovative biological drug products and treatment protocols which harness the power of the human immune system to provide patients with cost-effective improved quality of life and curative or life-extending treatment options.For more information, contact Karen Leathers, President. email@example.com 1.913.663.3100The Chase Group. Proudly connecting life-saving executives and companies for over 25 years.